CERS
Cerus Corporation · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 365.56K | $864,980 | n/a | n/a |
| Q2 2026 | 77 | +3 | 100.93M | $293.62M | +6 | −3 |
| Q1 2026 | 76 | -1 | 93.85M | $170.85M | +2 | −3 |
| Q4 2025 | 77 | +2 | 97.51M | $200.87M | +2 | n/a |
| Q3 2025 | 17 | 0 | 78.06M | $124.11M | n/a | n/a |
| Q2 2025 | 14 | 0 | 72.85M | $102.72M | n/a | n/a |
| Q1 2025 | 11 | -1 | 42.94M | $59.69M | n/a | −1 |
| Q4 2024 | 12 | -1 | 40.64M | $62.59M | n/a | −1 |
| Q3 2024 | 12 | 0 | 39.10M | $68.03M | n/a | n/a |
| Q2 2024 | 12 | n/a | 38.88M | $68.43M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 315.05K | -50.0% | $749,819 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 50.51K | -51.1% | $115,161 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 166 holders, 151.51M shares, $268.19M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 30.00K sh · $89,529
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology